Respicardia launches Remed ē system, taps Sommerness as CEO

Respicardia said today it launched its Remedē transvenous implantable neurostimulation system designed to treat patients with central sleep apnea, and that it named Peter Sommerness as CEO. The Remedē system consists of a surgically placed battery pack and thin wires inserted into the blood vessels in the chest near the phrenic nerve, which it stimulates to engage the diaphragm to restore natural breathing during sleep and improve patient quality of life and satisfaction. “Central sleep apnea is very common in cardiac patients, especially patients with heart failure, and is associated with a significantly greater risk for morbidity and mortality. Being able to treat CSA offers a new hope to improve the quality of life for my patients,” Dr. William Abraham of the Ohio State University Wexner Medical Center said in prepared remarks. The procedure treating the first patient was performed by Dr. Ralph Augostini at Columbus’ Ohio State University Wexner Medical Center, the Minnetonka, Minn.-based company said. “The Remedē System is a breakthrough technology that uniquely treats central sleep apnea while greatly improving a patient’s quality of life. I am proud to be a part of the system’s first U.S. commercial case that has the potential to become the standard of care for these patients,” Dr. Augostini said in a prepared statement. Prior to joining Respicardia, Sommerness served as a partner at McKinsey and Company, and has held th...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News Neuromodulation/Neurostimulation Respiratory Respicardia Source Type: news